Abbott After the Flush: A High-Quality Compounder Trading Like a Story Broke
Abbott just printed a painful post-earnings air pocket and tagged a fresh 52-week low near $105.78. The selloff looks more like a reset of expectations than a permanent impairment: ABT still carries strong profitability (ROE ~27%), low leverage (debt-to-equity ~0.25), and meaningful free cash flow (~$6.9B). With RSI deeply oversold (~16) and heavy …